<node id="691086">
  <nid>691086</nid>
  <type>event</type>
  <uid>
    <user id="35486"><![CDATA[35486]]></user>
  </uid>
  <created>1783707851</created>
  <changed>1784893933</changed>
  <title><![CDATA[Immunoengineering Trainee Seminar]]></title>
  <body><![CDATA[<h6><br><strong>Featured Speakers:&nbsp;</strong><br>&nbsp;</h6><p>“<em>Engineered Nanowires for miRNA-Mediated Control of T Cell Exhaustion</em>” - Shaylyn Grier, Ph.D. student, Ankur Singh, Advisor.</p><h6>Abstract</h6><p>Persistent antigen exposure in cancer and chronic infection can drive T cell exhaustion, limiting the long-term effectiveness of adoptive cell therapies. A stem-like subset of exhausted T cells, known as progenitor exhausted T cells (Texprog), is associated with more durable immune responses and improved responses to immunotherapy, but is often present at low and variable levels. Here, we developed a silicon nanowire-based platform to deliver regulatory microRNAs directly into naïve mouse and human T cells, enabling early cellular programming before differentiation. Across mouse and human tumor models, including a three-dimensional diffuse large B-cell lymphoma organoid system, microRNA delivery increased features associated with Texprog, reduced signs of terminal exhaustion, improved cell survival, and maintained T cell function. These findings suggest that nanowire-mediated microRNA delivery can guide T cells toward a more persistent and therapeutically beneficial state, providing a promising strategy to enhance the effectiveness of adoptive T cell therapies.</p><p>"<em>Transcriptional Drivers of Impaired B Cell Immunity in Lymphoma Survivors</em>" - Rachel Ringquist, Ph.D., Ankur Singh, Advisor.</p><h6>Abstract</h6><p>R-CHOP, a combination of chemotherapy and the anti-CD20 antibody rituximab, is the standard first-line treatment for diffuse large B-cell lymphoma (DLBCL). While highly effective, recent studies have shown that patients treated with R-CHOP exhibit significantly diminished B cell responses even years after treatment concludes. Here, we aimed to identify transcriptional drivers of these diminished responses using an in vitro immune organoid platform that recapitulates B cell activation and maturation within the lymph node microenvironment. We profiled B cells from lymphoma survivors and found that our organoid system stratified donors into low, moderate, and high responders following influenza stimulation. Using single-cell RNA sequencing we identified unique transcriptional programs driving the observed functional differences between low and high responders. Furthermore, through single-cell BCR sequencing, we identified key differences in the clonal B cell responses between high and low responders. These results demonstrate that immune organoids can capture clinically meaningful heterogeneity in post-treatment B cell function, offering a platform for dissecting the mechanisms underlying impaired humoral immunity in lymphoma survivors.&nbsp;</p><p><em>The Immunoengineering Training Seminar Series is supported by the NIH T32 Research Training Program in Immunoengineering and housed within the&nbsp;</em><a href="https://immunoengineering.gatech.edu/"><em><strong>Center for Immunoengineering at Georgia Tech</strong></em></a><em>.&nbsp;</em></p>]]></body>
  <field_summary_sentence>
    <item>
      <value><![CDATA[Rachel Ringquist, Ph.D. and Shaylyn Grier Ph.D. Student, Ankur Singh, Advisor]]></value>
    </item>
  </field_summary_sentence>
  <field_summary>
    <item>
      <value><![CDATA[<p>Rachel Ringquist, Ph.D. and Shaylyn Grier Ph.D. Student, Ankur Singh, Advisor</p>]]></value>
    </item>
  </field_summary>
  <field_time>
    <item>
      <value><![CDATA[2026-07-31T13:00:00-04:00]]></value>
      <value2><![CDATA[2026-07-31T14:00:00-04:00]]></value2>
      <rrule><![CDATA[]]></rrule>
      <timezone><![CDATA[America/New_York]]></timezone>
    </item>
  </field_time>
  <field_fee>
    <item>
      <value><![CDATA[]]></value>
    </item>
  </field_fee>
  <field_extras>
      </field_extras>
  <field_audience>
          <item>
        <value><![CDATA[Faculty/Staff]]></value>
      </item>
          <item>
        <value><![CDATA[Postdoc]]></value>
      </item>
          <item>
        <value><![CDATA[Graduate students]]></value>
      </item>
      </field_audience>
  <field_media>
      </field_media>
  <field_contact>
    <item>
      <value><![CDATA[]]></value>
    </item>
  </field_contact>
  <field_location>
    <item>
      <value><![CDATA[Petit Biotech Building (IBB), Suddath Seminar Room 1128, 315 Ferst Drive]]></value>
    </item>
  </field_location>
  <field_sidebar>
    <item>
      <value><![CDATA[]]></value>
    </item>
  </field_sidebar>
  <field_phone>
    <item>
      <value><![CDATA[]]></value>
    </item>
  </field_phone>
  <field_url>
    <item>
      <url><![CDATA[]]></url>
      <title><![CDATA[]]></title>
            <attributes><![CDATA[]]></attributes>
    </item>
  </field_url>
  <field_email>
    <item>
      <email><![CDATA[]]></email>
    </item>
  </field_email>
  <field_boilerplate>
    <item>
      <nid><![CDATA[]]></nid>
    </item>
  </field_boilerplate>
  <links_related>
      </links_related>
  <files>
      </files>
  <og_groups>
          <item>1292</item>
      </og_groups>
  <og_groups_both>
          <item><![CDATA[Parker H. Petit Institute for Bioengineering and Bioscience (IBB)]]></item>
      </og_groups_both>
  <field_categories>
          <item>
        <tid>1795</tid>
        <value><![CDATA[Seminar/Lecture/Colloquium]]></value>
      </item>
      </field_categories>
  <field_keywords>
          <item>
        <tid>187423</tid>
        <value><![CDATA[go-bio]]></value>
      </item>
          <item>
        <tid>189814</tid>
        <value><![CDATA[go-researchevents]]></value>
      </item>
          <item>
        <tid>126601</tid>
        <value><![CDATA[go-ImmunoEngineering]]></value>
      </item>
      </field_keywords>
  <field_userdata><![CDATA[]]></field_userdata>
</node>
